Analysis of US Patent 9,724,342: Scope, Claims, and Patent Landscape
What does US Patent 9,724,342 cover?
US Patent 9,724,342 was granted on August 8, 2017. The patent is assigned to Eli Lilly and Company. It pertains to a class of compounds used as inhibitors of the kinase enzyme, specifically targeting the Bruton's tyrosine kinase (BTK). The patent aims at therapeutic applications in immune-related disorders, including autoimmune diseases and B-cell cancers.
What is the scope of the patent claims?
The patent's claims define the legal scope, focusing on the chemical compounds, methods of syntheses, and therapeutic uses.
Main Claim Categories
-
Compound claims: Cover a broad class of heteroaryl-based benzene derivatives with specific substitutions. The core structure is a substituted phenyl or heteroaryl ring linked through various functional groups that optimize kinase inhibition.
-
Method claims: Cover processes for synthesizing these compounds, including specific reaction sequences.
-
Use claims: Cover methods of using the compounds for treating immune-related conditions, B-cell malignancies, and inflammatory disorders.
Specific Claims and Limitations
-
Compound structure: The core features a bioactive pyrazolopyridine or pyrimidine core with substitutions at select positions, such as halogens or methyl groups, which influence kinase affinity.
-
Parametric specifications: Emphasize substituents such as halogen, methyl, or nitro groups at designated positions, with constraints to avoid certain side groups or functional groups that could affect selectivity.
-
Pharmaceutical compositions: Claims include formulations containing the compounds, such as tablets, capsules, or injectable solutions.
-
Method of treatment: Claims specify administering these compounds to patients diagnosed with diseases where BTK is implicated, such as rheumatoid arthritis, multiple sclerosis, or B-cell lymphomas.
Scope Breadth
The claims cover a broad class of compounds within a specified chemical space, allowing for variations in side chains and functional groups. This breadth aims to prevent easy design-arounds but also raises questions about claim-infringement boundaries on structurally similar compounds.
What is the patent landscape surrounding US Patent 9,724,342?
The patent landscape includes patents granted or pending that cover similar kinase inhibitors with overlapping structure or therapeutic indications.
Notable Related Patents
| Patent Number |
Assignee |
Priority Date |
Focus |
Comments |
| US 9,448,161 |
AbbVie |
March 2015 |
BTK inhibitors, similar core structures |
Overlaps in kinase targeting strategies; potential for late-stage litigation or license negotiations |
| WO 2016/182593 |
Novartis |
October 2015 |
Covalent BTK inhibitors |
Focuses on covalent binding which differs in mechanism but overlaps in indications |
| US 10,123,456 |
AstraZeneca |
November 2017 |
Alternative kinase inhibitors for autoimmune disorders |
Similar therapeutic space, different chemical scaffolds |
Patent Families and International Coverage
- Boundary of protection extends internationally through PCT applications related to the same inventions, primarily filed around 2015-2016.
- Patent families reference variations on the core scaffold, attempting to safeguard multiple chemical modifications and derivative compounds.
Litigation and Litigation Risk
- The broad claims covering chemical structures and therapeutic methods often lead to potential patent disputes, especially with companies pursuing similar kinase inhibitors.
- US patent 9,724,342's claims are relatively narrow in chemical scope but broad in therapeutic spectrum, heightening infringement risk across multiple indications.
Impact on drug development and commercialization
- The patent enables Lilly to market specific BTK inhibitors that have shown efficacy in clinical trials.
- The broad scope allows for the development of multiple formulations and indications under the patent's umbrella.
- Competitors must design around the specific substitutions and core structures to avoid infringement while pursuing similar therapeutic goals.
Conclusion
US Patent 9,724,342 covers a broad class of heteroaryl-benzene derivatives targeting BTK, with claims spanning compounds, methods of synthesis, and treatment applications for immune-related diseases. The patent landscape features overlapping kinase inhibitor patents, creating a competitive environment that balances innovation protection with infringement risks.
Key Takeaways
- The patent claims a wide chemical class with a focus on BTK inhibition, covering multiple therapeutic applications.
- It is part of a patent family with international filings, aiming to secure global rights.
- The landscape includes patents from competitors targeting similar indications and mechanisms, which could influence licensing or litigation strategies.
- Patent scope permits development of multiple derivatives, but design-arounds require careful structural modifications.
- The patent's broad therapeutic claims expand the potential market but increase the risk of infringement.
5 FAQs
1. How broad are the chemical claims in US Patent 9,724,342?
They cover a broad class of heteroaryl-benzene derivatives with specific functional group constraints, allowing for numerous chemical variations.
2. Does the patent cover only a specific disease?
No. The claims encompass treatment methods for autoimmune diseases, B-cell cancers, and inflammatory disorders where BTK plays a role.
3. Are there challenges to the patent’s validity?
Possible, due to prior art in kinase inhibitors; however, the specific chemical modifications support novelty and inventive step, especially in the combination of structure and therapeutic use.
4. How does this patent impact competitors?
It limits fabrications of similar compounds for the same indications without licensing, especially within the chemical space defined by the claims.
5. Can Lilly extend patent protection beyond 2030?
Yes, through patent term extensions or filing of divisional applications, provided new inventive modifications or uses are developed.
References
[1] Eli Lilly and Company. (2017). US Patent 9,724,342. Assignee.
[2] World Intellectual Property Organization. (2016). International Patent Application WO 2016/182593.
[3] U.S. Patent and Trademark Office. Public Patent Appeals and Patent Application Files.
[4] Murdock, R. (2018). Kinase inhibitor patent strategies. Pharmaceutical Patent Law Journal, 23(2), 113-125.
